ClinicalTrials.gg
CompletedNCT02065622Updated Nov 23, 2020Results posted

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

A Phase 3 interventional study of Adalimumab and Placebo in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 173 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
952
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
Largest of 18
952 · median 152
Started
2014
with 1 other
Phase 3
10 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
4 of 18
AbbVie

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one has the largest enrollment, is one of 2 that started in 2014, is one of 10 in phase 3, and was the 10th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.
  • Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral or or both. Mayo Score is confirmed by central reader.

Exclusion criteria

Exclusion Criteria:

  • Subject with Crohn's disease (CD) or indeterminate colitis (IC).
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
  • Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • Chronic recurring infections or active tuberculosis (TB).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
952 participants (actual)

Study arms

  • Experimental
    Induction (Main Study + Japan Sub-study): I-SD

    Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.

    Drug: Adalimumab · Other: Placebo

  • Experimental
    Induction (Main Study + Japan Sub-study): I-HD

    Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.

    Drug: Adalimumab

  • Experimental
    Maintenance (Main Study + Japan Sub-study): M-SD

    Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.

    Drug: Adalimumab · Other: Placebo

  • Experimental
    Maintenance (Main Study + Japan Sub-study): M-HD

    Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.

    Drug: Adalimumab

  • Experimental
    Maintenance (Main Study): TDM Regimen

    Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.

    Drug: Adalimumab · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Week 8

  2. Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Week 52

Secondary outcomes

  1. Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: Week 8

  2. Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 8

    Time frame: Week 8

  3. Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Week 8

  4. Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.

    Time frame: Week 8

  5. Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: Week 8

  6. Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.

    Time frame: Week 8

  7. Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.

    Time frame: Week 8

  8. Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: Week 52

  9. Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.

    Time frame: Week 52

  10. Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore \> 1.

    Time frame: Week 52

  11. Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopy subscore provided by the central reader.

    Time frame: Week 52

  12. Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.

    Time frame: Week 52

  13. Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

    Time frame: Week 52

  14. Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

    Time frame: Week 52

  15. Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Week 52

  16. Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

    Time frame: Week 52

  17. Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

    Time frame: Week 52

  18. Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: Week 52

  19. Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: Week 52

  20. Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.

    Time frame: Week 52

  21. Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 \[severe problem\] to 7 \[normal health\]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.

    Time frame: Week 52

07

Results

Posted Oct 8, 2020

Participant flow

This study included a Main Study (120 sites in 19 countries) and a Japan Sub-Study (22 sites in Japan). After a 3-week screening period, participants were randomized 3:2 to an 8-week double-blind (DB) Induction Period with 2 adalimumab dosing regimens (Induction Standard Dose \[I-SD\] or Induction Higher Dose \[I-HD\]).

Induction Study
Participant flow — Induction Study
MilestoneInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HDMaintenance (Main Study): TDM Regimen
Started379573000
Enrolled in main study340512000
Enrolled in japan sub-study3961000
Completed332514000
Not completed4759000
Withdrew: Adverse event1319000
Withdrew: Withdrawal by subject35000
Withdrew: Lost to follow-up10000
Withdrew: Lack of efficacy2227000
Withdrew: Requires alternative/prohibited therapy45000
Withdrew: Subject noncompliance11000
Withdrew: Other, not specified32000
Maintenance Study
Participant flow — Maintenance Study
MilestoneInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HDMaintenance (Main Study): TDM Regimen
Started00345350151
Completed00221246105
Not completed0012410446
Withdrew: Adverse event00252211
Withdrew: Withdrawal by subject001157
Withdrew: Lost to follow-up00411
Withdrew: Lack of efficacy00705519
Withdrew: Requires alternative/prohibited therapy00734
Withdrew: Subject non-compliance00132
Withdrew: Other, not specified006142
Withdrew: Unknown reason00010

Outcome measures

PrimaryInduction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 810.913.311.613.8
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.269 · Adjusted risk difference: 2.5 · 95% CI -2.0 to 7.0Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Breslow-Day test · p = 0.447Breslow-Day test of homogeneity across strata.
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.301 · Adjusted risk difference: 2.3 · 95% CI -2.0 to 6.6Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Breslow-Day test · p = 0.502Breslow-Day test of homogeneity across strata.
PrimaryMaintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 5229.039.530.141.1
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.069 · Adjusted risk difference: 9.9 · 95% CI -0.8 to 20.6Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Breslow-Day test · p = 0.085Breslow-Day test of homogeneity across strata.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.045 · Adjusted risk difference: 10.3 · 95% CI 0.2 to 20.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Breslow-Day test · p = 0.106Breslow-Day test of homogeneity across strata.
SecondaryInduction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 827.131.126.930.5
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.181 · Adjusted risk difference: 4.2 · 95% CI -2.0 to 10.5Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.200 · Adjusted risk difference: 3.8 · 95% CI -2.0 to 9.7Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 827.131.126.930.5
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.300 · Adjusted risk difference: 3.0 · 95% CI -2.6 to 8.6Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.254 · Adjusted risk difference: 3.1 · 95% CI -2.2 to 8.4Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 860.967.260.765.3
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.050 · Adjusted risk difference: 6.5 · 95% CI -0.0 to 13.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.131 · Adjusted risk difference: 4.8 · 95% CI -1.4 to 11.0Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 840.047.138.847.3
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.035 · Adjusted risk difference: 7.3 · 95% CI 0.5 to 14.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted risk difference: 8.7 · 95% CI 2.3 to 15.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 810.013.110.012.9
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.160 · Adjusted risk difference: 3.2 · 95% CI -1.3 to 7.6Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.166 · Adjusted risk difference: 2.9 · 95% CI -1.2 to 7.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 863.271.363.169.8
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.011 · Adjusted risk difference: 8.3 · 95% CI 1.9 to 14.7Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.025 · Adjusted risk difference: 7.0 · 95% CI 0.9 to 13.0Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryInduction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8
percentage of participantsInduction (Main Study): I-SDInduction (Main Study): I-HDInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HD
Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 857.161.157.559.9
Statistical analysis
  • Induction (Main Study): I-SD vs Induction (Main Study): I-HD · Cochran-Mantel-Haenszel · p = 0.218 · Adjusted risk difference: 4.2 · 95% CI -2.5 to 10.9Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
  • Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD · Cochran-Mantel-Haenszel · p = 0.456 · Adjusted risk difference: 2.4 · 95% CI -4.0 to 8.8Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryMaintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 5241.451.341.752.0
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.098 · Adjusted risk difference: 9.5 · 95% CI -1.7 to 20.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.066 · Adjusted risk difference: 9.9 · 95% CI -0.7 to 20.5Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 5253.374.754.474.1
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted risk difference: 21.5 · 95% CI 7.6 to 35.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.003 · Adjusted risk difference: 19.7 · 95% CI 6.6 to 32.7Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 5227.238.928.239.8
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.093 · Adjusted risk difference: 11.5 · 95% CI -1.9 to 25.0Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.088 · Adjusted risk difference: 11.1 · 95% CI -1.7 to 23.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopy subscore provided by the central reader.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 5240.557.144.455.8
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.161 · Adjusted risk difference: 15.9 · 95% CI -6.3 to 38.2Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.312 · Adjusted risk difference: 10.4 · 95% CI -9.8 to 30.6Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 5251.464.355.661.5
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.272 · Adjusted risk difference: 12.3 · 95% CI -9.7 to 34.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.600 · Adjusted risk difference: 5.3 · 95% CI -14.6 to 25.2Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 5253.877.856.371.4
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.074 · Adjusted risk difference: 23.8 · 95% CI -2.3 to 49.9Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.210 · Adjusted risk difference: 15.0 · 95% CI -8.5 to 38.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 5234.655.637.551.4
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.151 · Adjusted risk difference: 20.0 · 95% CI -7.3 to 47.3Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.299 · Adjusted risk difference: 12.8 · 95% CI -11.3 to 36.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 5262.166.462.665.7
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.422 · Adjusted risk difference: 4.5 · 95% CI -6.4 to 15.3Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.513 · Adjusted risk difference: 3.4 · 95% CI -6.8 to 13.6Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 5212.115.812.116.0
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.351 · Adjusted risk difference: 3.7 · 95% CI -4.1 to 11.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.292 · Adjusted risk difference: 3.9 · 95% CI -3.3 to 11.1Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 5217.422.917.023.8
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.121 · Adjusted risk difference: 5.4 · 95% CI -1.4 to 12.1Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.046 · Adjusted risk difference: 6.5 · 95% CI 0.1 to 12.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 5227.635.527.035.4
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.159 · Adjusted risk difference: 7.5 · 95% CI -2.9 to 17.9Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.109 · Adjusted risk difference: 8.0 · 95% CI -1.8 to 17.9Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic remission is defined as an endoscopy subscore of 0.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 5245.947.642.244.2
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.903 · Adjusted risk difference: 1.4 · 95% CI -21.0 to 23.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.901 · Adjusted risk difference: 1.3 · 95% CI -18.8 to 21.3Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 5262.169.762.671.4
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.160 · Adjusted risk difference: 7.7 · 95% CI -3.0 to 18.4Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.076 · Adjusted risk difference: 9.1 · 95% CI -0.9 to 19.1Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
SecondaryMaintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 \[severe problem\] to 7 \[normal health\]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52
percentage of participantsMaintenance (Main Study): M-SDMaintenance (Main Study): M-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HD
Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 5253.861.255.259.4
Statistical analysis
  • Maintenance (Main Study): M-SD vs Maintenance (Main Study): M-HD · Cochran-Mantel-Haenszel · p = 0.207 · Adjusted risk difference: 7.3 · 95% CI -4.0 to 18.6Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.
  • Maintenance (Main Study + Japan Sub-study): M-SD vs Maintenance (Main Study + Japan Sub-study): M-HD · Cochran-Mantel-Haenszel · p = 0.440 · Adjusted risk difference: 4.2 · 95% CI -6.4 to 14.8Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.

Adverse events

Collected over See time frame specifics detailed for each reporting group in their respective descriptions below. Participants were contacted 70 days following study drug discontinuation for an assessment of any new or ongoing adverse events, except those participants who continued on adalimumab therapy after the end of study participation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction (Main Study + Japan Sub-study): I-SD2/379 (0.5%)19/379 (5%)74/379 (19.5%)
Induction (Main Study + Japan Sub-study): I-HD4/573 (0.7%)22/573 (3.8%)112/573 (19.5%)
Maintenance (Main Study + Japan Sub-study): M-SD2/345 (0.6%)44/345 (12.8%)140/345 (40.6%)
Maintenance (Main Study + Japan Sub-study): M-HD2/350 (0.6%)44/350 (12.6%)141/350 (40.3%)
Maintenance (Main Study): TDM Regimen0/151 (0%)15/151 (9.9%)47/151 (31.1%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HDMaintenance (Main Study): TDM Regimen
COLITIS ULCERATIVEGastrointestinal disorders12/37913/57316/34518/3506/151
PNEUMONIAInfections and infestations1/3790/5732/3454/3500/151
CLOSTRIDIUM DIFFICILE INFECTIONInfections and infestations0/3791/5733/3450/3500/151
ANAEMIABlood and lymphatic system disorders3/3792/5731/3453/3500/151
MALLORY-WEISS SYNDROMEGastrointestinal disorders0/3790/5730/3450/3501/151
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/3790/5730/3450/3501/151
UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/3790/5730/3450/3501/151
BILE DUCT STONEHepatobiliary disorders0/3790/5730/3450/3501/151
PORTOSPLENOMESENTERIC VENOUS THROMBOSISHepatobiliary disorders0/3790/5730/3450/3501/151
BRONCHITISInfections and infestations0/3790/5730/3450/3501/151
Most frequent other events
Most frequent other events
EventInduction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDMaintenance (Main Study + Japan Sub-study): M-SDMaintenance (Main Study + Japan Sub-study): M-HDMaintenance (Main Study): TDM Regimen
COLITIS ULCERATIVEGastrointestinal disorders20/37918/57360/34547/35023/151
NASOPHARYNGITISInfections and infestations16/37929/57347/34546/35011/151
HEADACHENervous system disorders23/37948/57317/34522/3508/151
ARTHRALGIAMusculoskeletal and connective tissue disorders11/37918/57323/34523/3505/151
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/3796/57322/34519/3509/151
RASHSkin and subcutaneous tissue disorders11/37910/57311/34520/3504/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
Mean40.2 ± 13.1440.5 ± 12.8940.4 ± 12.98
Sex: Female, Male
Sex: Female, Male(Participants)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
Female166239405
Male213334547
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
White326484810
Black or African American81624
Asian4470114
Native Hawaiian/Other Pacific Islander011
Multiracial112
Missing011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
Hispanic or Latino192847
Japanese3961100
Other, Not Specified321484805
Region
Region(Participants)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
United States65113178
Non-United States314460774
Full Mayo Score (FMS)
Full Mayo Score (FMS)(units on a scale)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
Mean8.69 ± 1.5098.87 ± 1.5718.80 ± 1.548
FMS: Rectal Bleeding Subscore
FMS: Rectal Bleeding Subscore(units on a scale)Induction (Main Study + Japan Sub-study): I-SDInduction (Main Study + Japan Sub-study): I-HDTotal
Mean1.68 ± 0.9551.75 ± 0.9671.72 ± 0.962
08

Study locations

173 sites
  • Digestive Health Specialists of the Southeast /ID# 127844
    Dothan, Alabama 36305, United States
  • Ucsd /Id# 122313
    La Jolla, California 92093, United States
  • Rocky Mountain Clinical Resear /ID# 122180
    Wheat Ridge, Colorado 80033, United States
  • Medical Research Ctr CT /ID# 122179
    Hamden, Connecticut 06518, United States
  • Gastro Florida /ID# 170619
    Clearwater, Florida 33756, United States
  • Research Associates of South Florida,LLC /ID# 170309
    Miami, Florida 33156, United States
  • Gastroenterology Group Naples /ID# 127806
    Naples, Florida 34102, United States
  • Shafran Gastroenterology Ctr /ID# 122320
    Winter Park, Florida 32789, United States
  • Atlanta Gastro Assoc /ID# 122336
    Atlanta, Georgia 30342, United States
  • Gastro Assoc of Central GA /ID# 122318
    Macon, Georgia 31201, United States
  • Northwestern University Feinberg School of Medicine /ID# 122183
    Chicago, Illinois 60611-2927, United States
  • University of Chicago /ID# 122302
    Chicago, Illinois 60637-1443, United States
  • Carle Foundation Hospital /ID# 135955
    Urbana, Illinois 61801, United States
  • Louisiana Research Ctr. LLC /ID# 141655
    Shreveport, Louisiana 71105-6800, United States
  • University of Maryland Med Ctr /ID# 169734
    Baltimore, Maryland 21201, United States
  • MGG Group, Inc.Chevy Chase Clinical Research /ID# 122238
    Chevy Chase, Maryland 20815, United States
  • University of Michigan Hospitals /ID# 122240
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic - Rochester /ID# 122244
    Rochester, Minnesota 55905-0001, United States
  • Ctr for Digest and Liver Dis /ID# 122182
    Mexico, Missouri 65265, United States
  • NYU Langone Long Island CRA /ID# 122177
    Great Neck, New York 11021, United States
  • Icahn School of Med Mt. Sinai /ID# 127047
    New York, New York 10029, United States
  • Charlotte Gastro Hepatology /ID# 122235
    Charlotte, North Carolina 28207, United States
  • Wake Research Associates, LLC /ID# 122157
    Raleigh, North Carolina 27612, United States
  • Consultants for Clinical Res /ID# 122304
    Cincinnati, Ohio 45219, United States
  • Dayton Gastroenterology, Inc. /ID# 127804
    Englewood, Ohio 45415, United States
  • Gastro United of Tulsa /ID# 125436
    Tulsa, Oklahoma 74135, United States
  • The Oregon Clinic- Gastro West /ID# 135273
    Portland, Oregon 97225, United States
  • University of Pittsburgh MC /ID# 122331
    Pittsburgh, Pennsylvania 15260, United States
  • Erlanger Institute for Clinica /ID# 129009
    Chattanooga, Tennessee 37403, United States
  • Gastro One /ID# 122339
    Germantown, Tennessee 38138, United States
  • Vanderbilt Univ Med Ctr /ID# 125496
    Nashville, Tennessee 37232-0011, United States
  • DHAT Research Institute /ID# 170616
    Garland, Texas 75044-2208, United States
  • Biopharma Informatic Research /ID# 171150
    Houston, Texas 77024-2420, United States
  • Austin Center for Clinical Research /ID# 125396
    Pflugerville, Texas 78660, United States
  • Texas Digestive Disease Consul /ID# 141677
    Southlake, Texas 76092, United States
  • Texas Digestive Disease Consul /ID# 141678
    Southlake, Texas 76092, United States
  • Advanced Research Institute /ID# 126147
    Ogden, Utah 84403, United States
  • University of Utah /ID# 122333
    Salt Lake City, Utah 84112-5500, United States
  • New River Valley Research Inst /ID# 127801
    Christiansburg, Virginia 24073, United States
  • University of Washington /ID# 169721
    Seattle, Washington 98109, United States
  • WI Center for Advanced Res /ID# 122178
    Milwaukee, Wisconsin 53215, United States
  • Froedtert & the Medical College of Wisconsin /ID# 122261
    Milwaukee, Wisconsin 53226-3522, United States
  • KH der Elisabethinen Linz GmbH /ID# 127184
    Linz, Oberoesterreich 4010, Austria
  • Medizinische Universitat Wien /ID# 127186
    Vienna, Wien 1090, Austria
  • Ordination Hainburg an der Don /ID# 127185
    Hainburg An Der Donau, 2410, Austria
  • Universitaetsklinik fuer Innere Medizin 1 /ID# 125944
    Salzburg, 5020, Austria
  • KH der Barmherzigen Brueder /ID# 127183
    St Veit An Der Glan, 9300, Austria
  • AZ Sint-Lucas /ID# 127187
    Ghent, 9000, Belgium
  • UZ Leuven /ID# 126739
    Leuven, 3000, Belgium
  • CHU de Liege /ID# 126740
    Liege, 4000, Belgium
  • University of Calgary /ID# 125715
    Calgary, Alberta T2N 4Z6, Canada
  • Zeidler Ledcor Centre /ID# 125713
    Edmonton, Alberta T6G 2X8, Canada
  • Winnipeg Regional Health Autho /ID# 125712
    Winnipeg, Manitoba R3A 1R9, Canada
  • Qe Ii Hsc /Id# 127045
    Halifax, Nova Scotia B3H 1V7, Canada
  • London Health Sciences Centre /ID# 127055
    London, Ontario N6A 5A5, Canada
  • Mount Sinai Hosp.-Toronto /ID# 126590
    Toronto, Ontario M5G 1X5, Canada
  • Toronto Digestive Disease Asso /ID# 127075
    Vaughan, Ontario L4L 4Y7, Canada
  • McGill Univ HC /ID# 127046
    Montreal, Quebec H3G 1A4, Canada
  • Hepato-Gastroenterologie HK s.r.o. /ID# 127188
    Hradec Kralove, 500 12, Czechia
  • ISCARE a.s. /ID# 127837
    Praha 9, 190 00, Czechia
  • Herlev Hospital /ID# 127191
    Herlev, Hovedstaden 2730, Denmark
  • Regionhospital Silkeborg /ID# 127190
    Silkeborg, 8600, Denmark
  • CHRU Lille - Hôpital Claude Huriez /ID# 127197
    Lille CEDEX, Hauts-de-France 59045, France
  • CHU NANCY - Hôpital Brabois Adultes /ID# 127196
    Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle 54511, France
  • CHU Amiens Picardie /ID# 127194
    Amiens CEDEX 1, Somme 80054, France
  • CHU Estaing /ID# 127848
    Clermont Ferrand, 63100, France
  • CHU Dijon /ID# 127861
    Dijon, 21000, France
  • CHU de Grenoble - Albet Michal /ID# 127195
    Grenoble, 38043, France
  • CHU Saint ELOI /ID# 169007
    Montpellier Cedex 5, 34295, France
  • CHU de Nice /ID# 127193
    Nice, 06202, France
  • CHU de Saint-Etienne, Hopital Nord /ID# 134490
    SAINT-ETIENNE Cedex 1, 42270, France
  • Hopital Rangueil /ID# 127192
    Toulouse, 31059, France
  • Universitatsklinik Regensburg /ID# 201265
    Ratisbon, Bayern 93053, Germany
  • Universitatsklinikum Frankfurt /ID# 170300
    Frankfurt, Hessen 60590, Germany
  • Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 127199
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 127203
    Berlin, 10117, Germany
  • Mross, Berlin, DE /ID# 127201
    Berlin, 10318, Germany
  • Gastrostudien GbR /ID# 169246
    Berlin, D-10825, Germany
  • Asklepios Westklinikum Hamburg /ID# 127198
    Hamburg, 22559, Germany
  • Universitaetsklinikum Jena /ID# 127205
    Jena, 07747, Germany
  • EUGASTRO GmbH /ID# 127202
    Leipzig, 04103, Germany
  • Universitatsklinikum Magdeburg /ID# 127200
    Magdeburg, 39120, Germany
  • Gastro Campus Research GbR /ID# 126743
    Munster, 48159, Germany
  • Pecsi Tudomanyegyetem Klinikai Kozpont I. sz. Belgyogyaszati Klinika /ID# 127209
    Pécs, Pecs 7624, Hungary
  • Magyar Elhizastudomanyi KKft. /ID# 126589
    Budapest, 1124, Hungary
  • Pannonia Maganorvosi Centrum Kft. /ID# 127207
    Budapest, 1136, Hungary
  • Szegedi Tudomanyegyetem /ID# 127208
    Szeged, 6720, Hungary
  • Rabin Medical Center /ID# 127212
    Petakh Tikva, Tel-Aviv 4941492, Israel
  • Tel Aviv Sourasky Medical Center /ID# 201365
    Tel Aviv-Yafo, Tel-Aviv 6423906, Israel
  • Soroka University Medical Center /ID# 127213
    Be'er Sheva, 84101, Israel
  • Hadassah University Hospital /ID# 127211
    Jerusalem, 91120, Israel
  • Kaplan Medical Center /ID# 127210
    Rehovot, 76100, Israel
  • A.O.U. Policlinico S.Orsola-Malpighi /ID# 129322
    Bologna, Emilia-Romagna 40138, Italy
  • Azienda Ospedaliera San Camillo Forlanini /ID# 127216
    Rome, Lazio 00152, Italy
  • Policlinico Agostino Gemelli /ID# 127217
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 127138
    Milan, Lombardia 20122, Italy
  • IBD Center - IRCCS Istituto Clinico Humanitas /ID# 127215
    Rozzano, Milano 20089, Italy
  • Azienda Ospedaliera Spedali Civili /ID# 127236
    Brescia, 25123, Italy
  • Universita di Padova /ID# 127214
    Padova, 35128, Italy
  • Ospedali Riuniti Villa Sofia-C /ID# 129323
    Palermo, 90146, Italy

Showing the first 100 of 173 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol. 2021 Oct 1;33(10):1274-1279. doi: 10.1097/MEG.0000000000002250. PubMed 34402466 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Sep 2019, 65 months.

Results were first posted in Oct 2020, 1 year 1 month after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 65 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Feb 19, 2014
StartActual
Mar 27, 2014
Primary completionActual
Sep 5, 2019
CompletionActual
Nov 11, 2019
Results first posted
Oct 8, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065622
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Mar 27, 2014
Primary completion
Sep 5, 2019
Completion
Nov 11, 2019
Results posted
Oct 8, 2020
Last update
Nov 23, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion